Healthcare

India’s healthcare industry is projected to expand dramatically, reaching an estimated $700 billion—approximately Rs. 58 lakh crore—by 2030. The sector’s rapid growth is being driven by rising healthcare demand, expanding insurance coverage, technological innovation, and increasing private investment. Major hospital chains, pharmaceutical companies, and digital health platforms are scaling operations to meet the needs of a growing and increasingly health-conscious population.

Healthcare provider Manipal Health Enterprises is preparing to launch an initial public offering (IPO) featuring a fresh issue of shares worth approximately Rs. 8,000 crore. The move is expected to support the company’s expansion strategy, strengthen its balance sheet and fund new hospital infrastructure across India. As the country’s healthcare sector continues to attract significant investor interest, the planned IPO highlights the growing role of private capital in healthcare delivery.

India’s health insurance industry has achieved a significant milestone, with total premiums surpassing Rs. 1.2 lakh crore during the financial year 2024–25. The surge reflects rising healthcare awareness, higher medical costs, and expanding coverage among both individuals and corporations. Industry data monitored by the Insurance Regulatory and Development Authority of India shows strong growth across private insurers, public sector providers, and government-backed schemes.

The tragic death of Vandana Das has remained a significant reference point in discussions about the safety of healthcare professionals and the legal responsibilities surrounding violent incidents in medical institutions. The young doctor lost her life in a violent attack while performing her duties, prompting widespread concern across India’s medical community. The subsequent legal proceedings have focused on determining accountability and ensuring justice through the courts.

India’s pharmaceutical sector has marked a significant milestone with the launch of a generic version of semaglutide, a widely recognized drug used to treat Type 2 diabetes and aid weight management. The introduction of the generic formulation is expected to significantly reduce treatment costs, potentially improving access for millions of patients struggling with metabolic disorders.